Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Sham-Controlled Trial of Renexus (CNTF Implant) in Macular Telangiectasia Type 2
2017-003234-82Phase 3Unknown
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- Oct 2017
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of revakinagene taroretcel-lwey in macular telangiectasia type 2 (MacTel) (2 arms), sponsored by Neurotech Pharmaceuticals, Inc. Primary endpoint: Rate of change in ellipsoid zone area loss. Status: unknown.
02
Drugs
revakinagene taroretcel-lwey
03
Conditions
macular telangiectasia type 2 (MacTel)
Beyond the preview
Go deeper on 2017-003234-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003234-82.